Pfizer · NSE: PFIZER · BSE: 500680
Q3 FY21 results · Oct–Dec 2020
Pfizer reported revenue from operations of ₹593.49 crore (up 10.3% from Q3 FY20) and net profit of ₹141.24 crore (up 1.6% from Q3 FY20) for Q3 FY21 (Oct–Dec 2020), on a standalone basis.
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 593.49 | 538.18 | +10.3% | 595.41 | −0.3% |
| Other income | 14.57 | 58.22 | −75.0% | 12.15 | +19.9% |
| Total income | 608.06 | 596.40 | +2.0% | 607.56 | +0.1% |
| Profit before tax | 180.26 | 164.50 | +9.6% | 183.03 | −1.5% |
| Net profit for the period | 141.24 | 139.06 | +1.6% | 131.37 | +7.5% |
| EPS, basic (₹) | 30.87 | 30.40 | +1.5% | 28.71 | +7.5% |
| Net margin (%) | 23.8 | 25.8 | 22.1 |
Standalone
- Filed with BSE
- 05 Feb 2021, 16:25 IST
- Board meeting
- 05 Feb 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE